144 related articles for article (PubMed ID: 27635409)
1. Canagliflozin-Induced Diabetic Ketoacidosis: Case Report and Review of the Literature.
Turner J; Begum T; Smalligan RD
J Investig Med High Impact Case Rep; 2016; 4(3):2324709616663231. PubMed ID: 27635409
[TBL] [Abstract][Full Text] [Related]
2. Canagliflozin-associated diabetic ketoacidosis: a case report.
Chai PR; Bonney C; Blohm E; Boyer EW; Babu KM
Toxicol Commun; 2017; 1(1):2-5. PubMed ID: 29978156
[TBL] [Abstract][Full Text] [Related]
3. Diabetic Ketoacidosis in Patients with Type 2 Diabetes on Sodium-Glucose Cotransporter-2 Inhibitors - A Case Series.
Sharma PV; Jobanputra YB; Lewin K; Bagatell S; Lichtstein DM
Rev Recent Clin Trials; 2018; 13(2):156-160. PubMed ID: 29542418
[TBL] [Abstract][Full Text] [Related]
4. Prolonged diabetic ketoacidosis associated with canagliflozin.
Sloan G; Kakoudaki T; Ranjan N
Endocrinol Diabetes Metab Case Rep; 2018; 2018():. PubMed ID: 29899991
[TBL] [Abstract][Full Text] [Related]
5. Euglycemic Diabetic Ketoacidosis with Elevated Acetone in a Patient Taking a Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor.
Andrews TJ; Cox RD; Parker C; Kolb J
J Emerg Med; 2017 Feb; 52(2):223-226. PubMed ID: 27717592
[TBL] [Abstract][Full Text] [Related]
6. Canagliflozin-associated Diabetic Ketoacidosis with Lower-than-anticipated Glucose Levels.
Vadi S; Agarwal M
Indian J Crit Care Med; 2017 Nov; 21(11):793-795. PubMed ID: 29279644
[TBL] [Abstract][Full Text] [Related]
7. Euglycemic Diabetic Ketoacidosis in a 27 year-old female patient with type-1-Diabetes treated with sodium-glucose cotransporter-2 (SGLT2) inhibitor Canagliflozin.
Bader N; Mirza L
Pak J Med Sci; 2016; 32(3):786-8. PubMed ID: 27375734
[TBL] [Abstract][Full Text] [Related]
8. SGLT-2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis: A Case Report and a Literature Review.
Mahfooz RS; Khan MK; Al Hennawi H; Khedr A
Cureus; 2022 Jun; 14(6):e26267. PubMed ID: 35911365
[TBL] [Abstract][Full Text] [Related]
9. Euglycemic Diabetic Ketoacidosis With Sodium-Glucose Cotransporter-2 Inhibitor Use Post-Bariatric Surgery: A Brief Review of the Literature.
Iqbal QZ; Mishiyev D; Zia Z; Ruggiero RA; Aftab G
Cureus; 2020 Oct; 12(10):e10878. PubMed ID: 33178530
[TBL] [Abstract][Full Text] [Related]
10. Euglycemic Diabetic Ketoacidosis With Prolonged Glucosuria Associated With the Sodium-Glucose Cotransporter-2 Canagliflozin.
Kelmenson DA; Burr K; Azhar Y; Reynolds P; Baker CA; Rasouli N
J Investig Med High Impact Case Rep; 2017; 5(2):2324709617712736. PubMed ID: 28634592
[TBL] [Abstract][Full Text] [Related]
11. Canagliflozin use in Type I diabetes mellitus.
Guthrie R
Postgrad Med; 2017 Apr; 129(3):336-339. PubMed ID: 27918226
[TBL] [Abstract][Full Text] [Related]
12. Euglycemic diabetic ketoacidosis caused by canagliflozin: a case report.
Fukuda M; Nabeta M; Muta T; Fukami K; Takasu O
Int J Emerg Med; 2020 Jan; 13(1):2. PubMed ID: 31969112
[TBL] [Abstract][Full Text] [Related]
13. Euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitor use: a case report and review of the literature.
Diaz-Ramos A; Eilbert W; Marquez D
Int J Emerg Med; 2019 Sep; 12(1):27. PubMed ID: 31488052
[TBL] [Abstract][Full Text] [Related]
14. Commentary: SGLT inhibitors in type 1 diabetes: Place in therapy and a risk mitigation strategy for preventing diabetic ketoacidosis - the STOP DKA protocol.
Rendell MS
Diabetes Obes Metab; 2019 Oct; 21(10):2189-2191. PubMed ID: 31334593
[TBL] [Abstract][Full Text] [Related]
15. Late-Onset Euglycemic Diabetic Ketoacidosis in a Patient With Massive Stroke Requiring Decompressive Craniectomy: A Case Report.
Hussaini SA; Aziz A; Musa M; Alamin M; Danjuma M
Cureus; 2021 Oct; 13(10):e18629. PubMed ID: 34765377
[TBL] [Abstract][Full Text] [Related]
16. Euglycemic Diabetic Ketoacidosis Due to Sodium-Glucose Cotransporter 2 Inhibitor Use in Two Patients Undergoing Pancreatectomy.
Pace DJ; Dukleska K; Phillips S; Gleason V; Yeo CJ
J Pancreat Cancer; 2018; 4(1):95-99. PubMed ID: 30631862
[No Abstract] [Full Text] [Related]
17. The DKA that wasn't: a case of euglycemic diabetic ketoacidosis due to empagliflozin.
Candelario N; Wykretowicz J
Oxf Med Case Reports; 2016 Jul; 2016(7):144-6. PubMed ID: 27471597
[TBL] [Abstract][Full Text] [Related]
18. Acute pancreatitis in the use of canagliflozin: A rare side-effect of the novel therapy for type 2 diabetes mellitus.
Srivali N; Thongprayoon C; Cheungpasitporn W; Ungprasert P
J Basic Clin Pharm; 2015 Jun; 6(3):101-2. PubMed ID: 26229348
[TBL] [Abstract][Full Text] [Related]
19. Euglycemic Diabetic Ketoacidosis in Concurrent Very Low-carbohydrate Diet and Sodium-glucose Transporter-2 Inhibitor Use: A Case Report.
Earle M; Ault B; Bonney C
Clin Pract Cases Emerg Med; 2020 May; 4(2):185-188. PubMed ID: 32426668
[TBL] [Abstract][Full Text] [Related]
20. Sudden-onset Hypoglycemia Following Fluid Replacement in a Patient with Dapagliflozin-induced Diabetic Ketoacidosis Without Prior Insulin Use: Case Report.
Elshimy G; Correa R
Cureus; 2019 Aug; 11(8):e5448. PubMed ID: 31489272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
